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Background: Osteoporosis is one of the prevalent diseases in ageing populations. Due to side effects of many
chemotherapeutic agents, there is always a need to search for herbal products to treat the disorder. Punica
granatum (PG) represent a potent fruit-bearing medicinal herb which exerted valuable anti-osteoporotic activities.
The present study was carried out to validate the in vitro osteogenic effects of the PG seed extract in primary
calvarial osteoblast cultures harvested from neonatal rats.
Methods: The ethanolic extract of PG was subjected to evaluate cell proliferation, regeneration, mineralization
and formation of collagen matrix using MTT, alkaline phosphatase, Alizarin Red-S staining and Sirius Red dye,
respectively. Cell cycle progression and osteogenic gene Runx2 expression were carried out by flow cytometry and
real time PCR, respectively.
Results: Exposure of different concentrations (10–100 μg/ml) of the extract on osteoblastic cells showed characteristic
morphological changes and increment in cell number. A significant growth in cell proliferation, ALP activity, collagen
contents and matrix mineralization of osteoblasts in a dose dependent manner (p < 0.05), suggested that PG has a
stimulatory effect on osteoblastic bone formation or potential activity against osteoporosis. In addition, PG extract
also enhanced DNA content in S phase of cell cycle and Runx2 gene expression level in osteoblasts.
Conclusion: The data clearly indicated that PG promoting bone cell proliferation and differentiation in primary
osteoblasts might be due to elevating the osteogenic gene Runx2 expression. The present study provides an
evidence for PG could be a promising herbal medicinal candidate that able to develop drugs for osteoporosis.
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Osteoporosis is a metabolic bone disorders that afflicts
about 200 million people worldwide. It is mainly prevalent
in women (approximately 80%) and also older men [1].
The bone remodeling process is the alternative of this se-
vere concern, and it’s dependable for repair of damage or
formation and resorption of bones to maintain the integ-
rity of the skeleton. However, any abnormalities in remod-
eling that lead to fracture in the bones and osteoporosis.
Recently, several conventional and antiresorptive drugs
are used to reduce fracture risk in osteoporosis including
hormone replacement therapy (HRT), bisphosphonates,* Correspondence: molendolab@gmail.com
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article, unless otherwise stated.selective estrogen receptor modulators (SERMs) and calci-
tonin [2]. However, these drugs and therapy have multiple
side effects, which causes heart related issues, headache,
dizziness, anorexia, cramping of legs and gastrointestinal
related problem, particularly pain in stomach and heart-
burn [3]. The research still continues for the enhancement
of such benefit to lower risk involved in human beings.
Anabolic or osteogenic therapies are preferred for
pharmacological development to treat osteoporosis [4].
Parathyroid hormone (PTH 1–34) only anabolic agent
for the treatment of postmenopausal osteoporosis that
is also recommended by the FDA (Food and Drug Admin-
istration) which regulates the formation of bones by
enhancing the cell proliferation of the osteoblastic lineage
or inducing differentiation of osteoblast progenitor cells.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cancer, such as osteosarcoma [5,6].
In the recent time, several medicinal plants are used
for health care treatments and management especially
bone related diseases. Although compared with other
drug treatments, herbal products create no/little side ef-
fects. Punica granatum (Pomegranate, PG) is one of the
most potent fruit-bearing medicinal herbs widely distrib-
uted throughout the Mediterranean region of southern
Europe, northern Africa and tropical Africa, Indian sub-
continent, Central Asia and the drier parts of South-East
Asia. PG seeds contain punicic acid, ellagic acid, ster-
oidal estrogen and non-steroidal phytoestrogens, includ-
ing comesten, coumoestrol and isoflavones genistein,
daidzein and ascorbic acids. PG also contains estrogenic
compound such as luteolin, quercetin, kaempferol, estrone
and estradiol, which are responsible for bone formation
and also inhibit the resorption process [7-12]. A non-
isoflavone phytoestrogenic compounds such as quercetin,
rutin, apigenin and coumestrol has also been reported in
various legumes [13]. A crude PG extract and its seed oil
enhance bone healing properties and prevent loss of bones
because of the proliferation of osteoblast, inhibition of
osteoclast cell and also decrease the inflammation. [14,15].
Recently, PG has been also utilized to inhibit acetyl cho-
linesterase activity as a new source for management of
Alzheimer’s disease [16].
Osteoblast differentiation and proliferation mediated
by different growth factors such as bone morphogenetic
proteins (BMPs), transforming growth factor beta (TGFβ)
and core-binding factor alpha1 (Cbfα1) are known to be
targeted the osteogenic Runt-related transcription factor2
(Runx2) gene [17]. Runx2 is the key transcription factor
initiating and regulating the early osteogenesis and late
mineralization of bone. Furthermore, Runx2 triggers the
expression of major bone matrix genes during the early
stages of osteoblast differentiation [18].
There is no evidence regarding the investigation of the
PG seed extract on bone cell proliferation, differentiation,
and collagen matrix formation in primary culture of
osteoblasts. The present study also described the matrix
mineralization activity along with osteogenic gene Runx2
expression by real time PCR and DNA content analysis in
the S phase of the cell cycle in osteoblastic cells. The find-
ings suggested that PG may be a potent osteogenic herbal
drug that induces bone cells proliferation and regeneration
following increased DNA contents and Runx2 gene ex-
pression which provide future prospects in the develop-
ment of anti-osteoporotic drugs and therapy.
Materials and methods
Reagents and chemicals
Alpha modified minimum essential medium (α-MEM),
fetal bovine serum (FBS), MTT (3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) dye, p-nitrophe-
nyl phosphate (pNPP), naphthol ASMX phosphate, fast
blue BB salt, ascorbic acid and Sirius Red dye were
purchased from Himedia, India. β-glycerophosphate,
Ribonuclease (RNase) A and propidium iodide (PI) were
purchased from Sigma-Aldrich, USA. RNAiso Plus re-
agent was procured from Takara, India. cDNA synthesis
kit was purchased from Thermo Scientific, USA and
SYBER green kit from Roche, USA. All the reagents
used were of high purity grade.
Plant materials and extraction
The fresh cultivated PG plant was collected from nearby
University of Lucknow, Lucknow, India. Plant materials
were identified and authenticated from Department of
Pharmacognosy, Faculty of Pharmacy, Integral University,
Lucknow. A reference specimen (voucher No. IU/PHAR/
HRB/14/08) has been deposited in the herbarium of Fac-
ulty of Pharmacy, Integral University, Lucknow. Seed parts
of collecting plant were air dried in the shade and crushed
to a powder in a mechanical grinder. The 95% ethanolic
extract of PG was prepared with the help of Soxhlet
apparatus (Borosil Glass Works Limited, India) at 60°C
and Whatman No. 1 filter paper was used to obtain fil-
trate of extract. The filtrate was concentrated in vacuum
at 40°C using a rotary evaporator (BUCHI Rotavapor
R-205, Switzerland).
Primary culture of osteoblasts
Osteoblastic cells were isolated from neonatal rat pups
calvaria using sequential digestion with slight modifica-
tion [19]. Briefly, calvaria were dissected from four to
five neonatal (1–2 days old) rat pups. After removal of
sutures and adherent mesenchymal tissues, calvaria were
subjected to five sequential (10–15 min) digestions at
37°C in shaking water bath at 120 rpm containing each
of 0.1% dispase and collagenase type II enzymes. Super-
natants were pooled from the second to fifth digestions
in a tube containing 800 μl FBS. Cells were re-suspended
in α-MEM containing 10% FBS with 1% penicillin/strepto-
mycin solution and transfer in T-25 cm2 culture flasks.
The flasks were incubated at 37°C with 5% CO2 in CO2
incubator (Excella ECO-170, New Brunswick). The study
was approved by the Institutional Animal Ethics Commit-
tee of Azad Institute of Pharmacy and Research, Lucknow
(Ref. No.: AIPR/2013-14/1398).
Cell proliferation
The proliferative effect of PG extract was determined using
MTT assay with some modification [20]. Calvarial osteo-
blasts were suspended in α-MEM medium and plated at a
density of 2 × 103 cells/well in a 96 wells plate. After over-
night incubation, the medium was replaced with a medium
containing PG extract solution prepared in media with
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triplicate for 48 h. 17β-estradiol (E2) at the concentration
of 1 nM was used as a positive control. After exposure
period, 10 μl of 5 mg/ml MTT solution was added to each
wells and further incubated at 37°C. After 4 h, medium
was discarded and 100 μl of dimethyl sulphoxide (DMSO)
was added to solubilise the dark blue formazan crystals at
37°C for 10 min. Absorbance was recorded at 540 nm with
microplate reader (BIORAD-680, USA) and the percentage
viable cells were calculated using the formula:
%Cell viability ¼ OD of treatedð Þ= OD of controlð Þ½   100
The cellular morphology was also observed in other
sets of PG treatment under trinocular inverted phase
contrast microscopy (Nikon ECLIPSE Ti-S, Japan).
Alkaline phosphatase (ALP) activity
ALP assay is based on the hydrolysis of pNPP by ALP
into a yellow colored product at alkaline pH. ALP activity
of osteoblasts was determined with a slight modification
[21]. A 100 μl of cell suspension containing 2 × 103cells
/well was seeded in 96-well plates using α-MEM supple-
mented with 10% FBS, 10 mM β-glycerophosphate, 50 μg/
ml ascorbic acid and 1% penicillin/streptomycin (osteo-
blast differentiation medium) and treated with different
concentrations (10–100 μg/ml) of the extract for 48 h. E2
at the concentration of 1 nM was used as a positive con-
trol. After completion of incubation period, osteoblast cul-
tures were fixed in 4% paraformaldehyde and stained with
a solution containing 0.1 mg/ml naphthol ASMX phos-
phate, 0.5% N, N- dimethylformamide, 2 mM MgCl2, and
0.6 mg/ml of fast blue BB salt in 0.1 mM Tris–HCl
(pH 8.5) for 20 min. The formation of color was examined
and images were taken under an inverted phase contrast
microscope. For the quantitative estimation of ALP, the
plate was fixed and kept in −70°C for 20 min, and then
brought to 37°C for freeze fracture. Next, 50 μl of chilled
p-nitrophenyl phosphate (pNPP) substrate was added to
each wells and incubated at 37°C for 30 min for color de-
velopment. The absorbance was measured at 405 nM
using an ELISA reader.
Assessment of collagen deposition
Sirius Red is an anionic dye that binds strongly to colla-
gen molecules. Collagen deposition was quantified using
Sirius Red dye following slightly modification [22]. Treated
cells were washed with PBS and dried at 37°C in 96-wells
plate for overnight incubation and then stained with 20 μl
of Sirius Red dye (0.1% in saturated picric acid) for 1 h
with mild shaking. Sirius Red dye solution (pH 3.5) was
prepared in saturated aqueous picric acid (1.3% in H2O) at
a concentration of 0.1 mg/ml. The stained cell layers were
extensively washed with 0.01 N HCl to remove all non-bounded dye. After rinsing, photographs were taken under
inverted phase contrast microscope. For quantitative ana-
lysis, the stained cells were dissolved in 0.2 ml 0.1 N
NaOH at shaker for 30 min. Next, absorbance was mea-
sured colorimetrically at 550 nm against 0.1 N NaOH
serve as a blank.
Mineralization assay
Alizarin Red S, an anthraquinone derivative, was used to
identify calcium content in osteoblasts according to a
method reported previously [23]. Approximately, 2 × 104
cells/well were seeded in 12-wells culture plate in osteo-
blast differentiation medium with 10−7 M dexamethasone.
Cells were treated with PG extract at various concentra-
tions (10–100 μg/ml) for 21 days and the medium was
changed every alternate day. At the end of the experiment,
cells were washed with PBS and fixed with 4% paraformal-
dehyde in PBS for 15 min. The fixed cells were stained
with 40 mM Alizarin Red-S (pH 4.5) for 30 min followed
by washing with distilled water. Calcified nodules appear-
ing as bright red color were photographed under inverted
phase contrast microscopy. For quantification of staining,
100 mM cetylpyridinium chloride solution was added for
1 h in each well to solubilise and to release calcium-
bound alizarin red into solution. A 100 μl of the super-
natant from each well were transferred in 96 well plate in
triplicate and the absorbance was recorded at 570 nm by a
microplate reader.
Cellular DNA content
Cell cycle phase distribution with cellular DNA content
was analyzed using flow cytometry with some modifica-
tion [24]. Osteoblasts were planted in 6-wells plate at a
density 1 × 106 cells/well and treated with different con-
centrations (10–100 μg/ml) of extract for 48 h. E2 at the
concentration of 10 nM was used as a positive control.
Cultured cells were washed with cold PBS and fixed in
70% ethanol at −20°C for 2 h. Fixed cells were treated
with RNase A (10 mg/ml) and stained with PI dye in the
dark for 30 min at room temperature. The PI dye fluor-
escence of individual nuclei was measured by using a
flow cytometer (BD FACS Calibur, Becton Dickinson,
USA) and data were analyzed using Cell Quest Pro V
3.2.1 software (Becton Dickinson, USA).
Quantitative real-time PCR (qPCR)
The total RNA was isolated from cultured osteoblasts
treated with PG extract using RNAiso Plus reagent.
Aliquots of 2.0 μg of total RNA in a 10 μl reaction vol-
ume were subjected to PCR using a cDNA synthesis kit.
Quantitative real-time PCR was performed in light cycler
PCR system (LightCycler 480, Roche, USA) using SYBER
green kit following manufacturer’s instruction. Runx2
gene expression in calvarial osteoblasts was determined
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primer pairs of the genes used in the present study
were; runx2- CCACAGAGCTATTAAAGTGACAGTG
(F), AACAAACTAGGTTTAGAGTCATCAAGC (R) and
GAPDH (housekeeping gene) - CAGCAAGGATACTGA
GAGCAAGAG (F), GGATGGAATTGTGAGGGAGATG
(R). All the data were normalized to GAPDH expression
to study the relative expression of the targeted gene.
Statistics
All results were represented as the means ± SEM of re-
sults from all replicates and statistically significance was
determined by one-way analysis of variance (ANOVA)
followed by Dunnett’s multiple comparison tests. Prob-
ability values of p < 0.05 were considered to be statistically
significant. All analysis was conducted using the Graph
Pad Prism (Ver. 5.1) software.
Results and discussion
Microscopic observation of osteoblastic cells
The morphological changes of untreated (control) and
treated osteoblasts with different concentrations of PG
extract at 48 h are shown in Figure 1A. The typical spin-
dle shaped with fibroblastic appearance was observed in
control under inverted phase contrast microscope. The
concentrations 10 and 25 μg/ml of extract enhanced the
cell proliferation, moreover, 50 and 100 μg/ml of PG
showed the more dense appearance with increased num-
ber of cells as compared to control that attributed differ-
entiation of osteoblastic cells. The results revealed that
cells exposed to PG extract induce differentiation of os-
teoblasts as a function of dose due to their morpho-
logical alterations and number of cells increment [26].
Effect of PG on the cell proliferation of osteoblasts
The effect of different doses (10–100 μg/ml) of PG ex-
tract on osteoblastic cell proliferation was tested at 48 h
(Figure 1B). As compared to control group (cells without
extract treatment), PG significantly increased the cellFigure 1 Percent cell proliferation of primary osteoblasts. (A) Morpho
with different concentrations of PG extract at 48 h (B) Percent cell prolifera
were obtained from three independent experiments and expressed as mea
with control.proliferation to 13.03 (p < 0.05) and 24.28% (p < 0.001) at
10 and 25 μg/ml, respectively. Moreover, 50 and 100 μg/
ml of PG extract induced cell proliferation to 39.64 and
62.59% (p < 0.001) respectively. The results revealed that
PG extract induced the significant cell proliferation in a
dose dependent manner. Exposure of cells to 1 nM of
17β-estradiol as a positive control, increased the cell
proliferation to 41.72% (p < 0.001) as compared to con-
trol. The proliferative effects of PG extract might be due
to their estrogenic nature of its contents, including quer-
cetin, kaempferol, estrone and estradiol, which promote
bone cell proliferation [11]. A study has shown that PG
promoted osteoblast MC3T3-E1 cell proliferation up to
approximately 2-fold at 250 μg/ml of plant extracts [7].
Both osteoblast and MCF-7 (human breast adenocarcin-
oma) cells are an estrogen receptor positive (ER+) cells.
A similar study has also revealed that MCF-7 cells ex-
posed to legume extracts containing quercetin, daidzein,
genistein and kaempferol glycosides at various concen-
trations (1–1000 μg/ml) showed a maximum cell prolif-
eration at 100 μg/ml of the extracts [27].
Effect of PG on ALP activity of osteoblasts
Quantitative estimation of alkaline phosphatase activity
is one of the biochemical methods, which described the
early cell differentiation of osteoblastic cells [28]. Fast
blue BB salt-ASMX-phosphate complex acted on ALP
activity which appeared to be blue in color. The qualita-
tive data showed that PG extract stimulated ALP stain
by increasing the rate of osteoblast cell differentiation in
a dose dependent manner (Figure 2A). As observed from
numerical data (Figure 2B), concentrations 10 and 25 μg/
ml of extract induced ALP level to 9.66% (p < 0.05) and
22.49% (p < 0.01) significantly as compared to control.
Also, 50 and 100 μg/ml of extract induced the significant
ALP level to 34.67 and 43.95% (p < 0.01) respectively as
compared to control. Exposure of cells to 1 nM of E2 in-
creased ALP activity to 36.66% (p < 0.01) as compared to
control. Results of ALP assay were the consistent withlogy of osteoblasts under inverted phase contrast microscope treated
tion of osteoblasts treated with 10–100 μg/ml of PG extract. Values
n ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 as compared
Figure 2 Measurement of ALP activity. (A) Photomicrographs
stained with fast blue BB salt-ASMX-phosphate complex showing
increased formation of ALP in osteoblasts treated with increasing
concentrations (10–100 μg/ml) of PG extract at 48 h (B) Quantitative
data of ALP level presented in the form of ALP activity relative to
control. Values are obtained from three independent experiments
and expressed as mean ± SEM. *p < 0.05 and **p < 0.01 as compared
with control.
Figure 3 Collagen formation assay of osteoblasts. (A)
Photomicrographs stained with Sirius Red dye showing increased
formation of collagen matrix of osteoblasts treated with increasing
concentrations (10–100 μg/ml) of PG extract at 48 h (B) Quantitative
data of collagen content expressed in the form of percent collagen
content respective to control. Data represented as mean ± SEM of
three independent experiments. **p < 0.01 and ***p < 0.001 as
compared with control.
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also correlate with cell differentiation. These results indi-
cate that PG extract induces regeneration of osteoblasts as
a function of dose might be due to the presence of estro-
genic compounds. PG containing estrogenic compounds
daidzein and genistein has been reported to possess
stimulatory effects synthesizing alkaline phosphatase by
osteoblasts in vitro [29].
Effect of PG on collagen deposition by osteoblasts
Sirius Red stain was used to assess the extent of collagen
(predominantly collagen type I and III fibers) deposited
by osteoblasts which developed dense and cross-linked
collagen. Collagen comprises 85-90% of the total organic
bone matrix [30]. Histological analysis showed that PG
extract increases collagen content in osteoblasts in a
dose dependent manner as compared to control. PG ex-
tract exposed on cells was able to enhance in the colla-
gen density significantly as evident by dark red clusters
of collagen evenly distributed throughout the stimulated
region (Figure 3A). Further, quantitative measurement of
the Sirius Red staining intensity in osteoblasts culture
showed a significant increment of 24.96 (p < 0.01), 62.40,
89.37 and 129.84% (p < 0.001) of collagen secretion at
10, 25, 50 and 100 μg/ml of PG exposure, respectively as
compared to control (Figure 3B). Exposure of osteo-
blasts to 1 nM of E2 increased the collagen content to
only 77.95% (p < 0.001) as compared to control. Bone
shows a variety of structural organizations which is re-
lated to the balance between the amount of collagenand mineral [31]. However, not only mineral matrix de-
position is essential to ensure a healthy bone, giving
strength and rigidity in the skeletal system, but also the
adequate deposition of organic matrix (collagen) contrib-
utes to bone architecture. Therefore, experiments were
conducted to determine whether PG extract exposure en-
hances the organic matrix deposition. PG treated osteo-
blasts progressively deposited more collagen (Figure 3A
and B) suggesting the collagen deposition induced by PG
is a function of dose. A study has reported that ascorbic
acid stimulates the formation of collagen matrix at mul-
tiple levels, including gene expression, hydroxylation of
proline and lysine in collagen during post-translational
modification [32].Effect of PG on osteoblast mineralization
Mineralized nodule formation describes the final stages
of osteoblastic differentiation at 21 days. As observed
from photomicrographs, osteoblastic cells in prolifera-
tion period exhibited a fibroblastic morphology mono-
layer in control cells. As the progress in mineralization,
the cells continued growing slowly and formed a mo-
saic like multiple layers which was greater at 100 μg/ml
of PG extract (Figure 4A). The percent calcification
data of Alizarin stain showed that treatment of osteoblasts
at 10, 25, 50 and 100 μg/ml of extract significantly in-
creased mineralized nodule formation that signifying by
26.15 (p < 0.01), 44.55, 65.64 and 82.81% (p < 0.001), re-
spectively as compared to control (Figure 4B). Exposure of
Figure 4 Mineralization assay of osteoblasts. (A) Photomicrographs
stained with Alizarin Red S showing increased formation of mineralized
nodules of osteoblasts treated with increasing concentrations
(10–100 μg/ml) of PG extract at 21 days (B) Quantitative data of
Alizarin Red-S extraction expressed in the form of percent calcification.
Data represented as mean ± SEM of three independent experiments.
**p < 0.01 and ***p < 0.001 as compared with control.
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content to 68.85% (p < 0.001) as compared to control.
Increased mineralization is synonymous to increased
calcium deposition. The ability to form an extracellular
matrix that can undergo regulated mineralization is the
ultimate phenotypic expression of an osteogenic tissue
[33]. PG treatment increased the calcium content not-
ably in the mineralized matrix at 21 days of osteoblasts
when compared with untreated cells. In this context,
the phytoestrogen genistein has been previously found
to stimulate bone mineralization in vitro [34].Figure 5 Analysis of DNA content by flow cytometry. Pictorial graph sh
cycle stained with PI dye of treated with 1 nM of E2 as a positive control aEffect of PG on cellular DNA content and cell cycle
distribution of osteoblasts
The cellular DNA content and proportion of cells in dif-
ferent phases of the cell cycle was analyzed by using flow
cytometry. Osteoblastic cells were treated with one lower
(25 μg/ml) and one higher concentration (100 μg/ml) of
the PG extract for 48 h and observed the different phases
of the cell cycle. As evident from the results (Figure 5), a
normal distribution of cell cycle was observed in the con-
trol group. At 25 μg/ml of PG extract, the accumulation
of cells (DNA content) in S phase was sharply increased
from 12.67 to 31.54% as compared to control. Moreover,
100 μg/ml concentration of the extract resulted to an in-
credible increment of DNA content in S phase by 78.72%
as compared to control. Exposure of osteoblasts to 1 nM
of E2 increased the DNA content in S phase by 44.08%
greater at 25 μg/ml of PG treatment. These data indicate
that the PG extract induce the cell proliferation by accu-
mulating the DNA content in S phase of the cell cycle. A
similar study has reported that estradiol induced the ex-
pression of estrogen receptor by promoting S phase of cell
cycle in human osteosarcoma cell lines and pilose antler
polypeptides promoted chondrocytes proliferation by ac-
celerating cell cycle progression in S phase [35,24].
Effect of PG on osteogenic gene runx2 expression
To determine these results could be extended to another
protein present in the organic bone matrix and effect of
PG on the expression of Runx2 gene. Runx2 is a noncol-
lagenous, highly conserved transcription factor involved
in the regulation of mineralized matrix of bone. Increased
expression of osteogenic gene was observed by qPCR in
osteoblasts treated with PG extract at 48 h. As cleared
from results (Figure 6), 10 μg/ml of PG extract signifi-
cantly elevated the Runx2 expression as compared toowing the proportion of osteoblastic cells in different phases of cell
nd 25 and 100 μg/ml of PG extract at 48 h.
Figure 6 Analysis of mRNA levels of Runx2 gene by qPCR.
Osteoblasts were treated with (10–100 μg/ml) of PG for 48 h. qPCR
for Runx2 mRNAs was performed. At each concentration, PG
increased the mRNA levels when compared to control. Fold changes
in mRNA levels are indicated by the numbers derived after normalizing
with GAPDH mRNA levels used as an internal control. Values are
obtained from three independent experiments in triplicate and
expressed as mean ± SEM; *p < 0.05, *p < 0.01 and ***p < 0.001 as
compared with control.
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100 μg/ml of PG increased the remarkable Runx2 level in
a dose dependent manner (p < 0.001) as compared to con-
trol. It has been reported that Runx2 bonds to the osteo-
blast specific cis acting element which is found in the
promoter region of all major osteoblast specific genes like
osteocalcin, type-I collagen, BSP, OPN, ALP and control
their expression [36]. Hence, it is reasonable to specu-
late that the estrogenic compounds such as β-sitosterol
present in PG could have acted in a manner to induce
mRNA expression of ALP, collagen and their protein
levels and consequently increased Runx2 gene expres-
sion in osteoblastic cells. Furthermore, flavonoids have
also been shown to increase the expression of Runx2
[37,38]. Thus, β-sitosterol and flavonoids present in PG
might be responsible for the increased expression and
transcriptional activity of Runx2.
Conclusion
The present study showed that osteogenic potential of PG
extract in primary calvaria osteoblasts is based on two sali-
ent features. (1) Cytochemical studies including cell prolif-
eration, ALP stain, collagenation, matrix mineralization
and DNA content in the S phase of the cell cycle in os-
teoblasts are the key parameters, which favor the osteo-
genic potential of PG. (2) A molecular marker Runx2 is
a highly conserved osteogenic transcription factor in-
volved in the regulation of bone cells proliferation and
differentiation, which is also favors the osteogenic na-
ture of PG.Even though E2 used as a positive control shows the
slightly higher effect on the proliferation, differentiation,
collagenation, mineralization, DNA content and Runx2
gene expression of osteoblasts than lower doses, however,
the side effects of the long-term use of estrogen, such as a
higher incidence of endometrial cancer, cardiovascular
disease and breast carcinoma, could not be ignored.
Thus, the results from this study suggest that PG pro-
motes the function of osteoblasts and plays an important
role in remodeling of the bone, which indicated that it
may be one of anti-osteoporotic herbal candidate free
from side effects. Accordingly, PG might be useful for al-
ternative pharmacological agent of osteoporosis and skel-
etal tissues may benefit from the consumption of PG.
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